Microsoft and Novartis will develop inputs through artificial intelligence

This joint work will take place in Switzerland.

The multinational company of pharmaceutical groups, Novartis and the big tech company, Microsoft; reach an agreement to work together to investigate the application of artificial intelligence (AI) on one of the most complex topics about health care: medicine.

Both companies will have a 5-year cooperation agreement; where Microsoft will specialize in developing new tools that can facilitate access to the application of artificial intelligence. It will be applied in different activities and habits that the Swiss company has. Business elements such as finance and manufacturing Novartis will be supervised by the IA de Microsoft.

Another part of working together will be using learning to improve the performance, precision and speed with which new AI drugs can be developed.

Vas Narasimhan, CEO of Novartis present make a difference with this alliance with Microsoft.

The executive director of Novartis, Vas Narasimhan; has explained and suggested that artificial intelligence may be something really promising within the field of personalized medicine; that is, it can help identify different types of patients who are much more likely to benefit from these new treatments. Narasimhan said that this collaboration agreement with Microsoft, make your company distinguish itself from other competitors. Narasimhan also hopes that it can make the cost reduction of drug discovery and other input development a reality. The cost of producing and marketing a new drug takes an average of 14 years, with high prices of up to $ 2.500 billion.

In recent years, the pharmaceutical industry has increased recognition and work on the potential of digital technologies and especially artificial intelligence. Therefore, companies are currently engaged in investigating elements such as metadata that could increase the speed of research development of new drugs.

Joint research by the companies will begin at the Novartis campus in Switzerland and at Microsoft's global research services center in Cambridge.

Remains of animal milk in old baby bottles